© 2018 LP-DG® Science

Exit.st0{fill:none;stroke:#FFFFFF;stroke-width:2;stroke-linecap:round;stroke-linejoin:round;stroke-miterlimit:10;} .st1{fill:none;stroke:#00d9ff;stroke-width:1;enable-background:new;} .st2{fill:none;stroke:#FFFFFF;stroke-width:1;enable-background:new;}
/front/assets/b0_bg.b9f56.png
/front/assets/b1.4d847.png
/front/assets/b2.06d15.png
/front/assets/b3.e5655.png
/front/assets/b4.6dac4.png
/front/assets/b5.2ecb4.png
/front/assets/b6.feb5a.png
/front/assets/b7.9e3a3.png
/front/assets/b8.f130a.png
/front/assets/b9.660ae.png
/front/assets/b10.47360.png
/front/assets/b11.f3d7e.png
/front/assets/b12.a0e95.png
The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study
DOI: 10.1007/s00345-020-03580-7

PURPOSE:
To evaluate the efficacy of Lactobacillus paracasei CNCM I-1572 (L. casei DG®) in both prevention of sympto-matic recurrences and improvement of quality of life in patients with chronic bacterial prostatitis (CBP).

METHODS:
Patients with CBP attending a single Urological Institution were enrolled in this phase IV study. At enrollment, all patients were treated with antibiotics in agreement with EAU guidelines and then were treated with L. casei DG® (2 capsules/day for 3 months).
Clinical and microbiological analyses were carried out before (enrollment, T0) and 6 months (T2) after the treatment.
Both safety and adherence to the treatment were evaluated 3 months (T1) after the enrollment.
NIH Chronic Prostatitis Symptom Index (CPSI), International Prostate Symptom Score (IPSS) and Quality of Well-Being (QoL) questionnaires were used. The outcome measures were the rate of symptomatic recurrence, changes in questionnaire symptom scores and the reduction of antibiotic use.

RESULTS:
Eighty-four patients were included. At T2, 61 patients (72.6%) reported a clinical improvement of symptoms with a return to their clinical status before symptoms. A time dependent improvement in clinical symptoms with significant changes in NIH-CPSI, IPSS and QoL (mean difference T2 vs T0: 16.5 ± 3.58; − 11.0 ± 4.32; + 0.3 ± 0.09; p < 0.001), was reported.
We recorded that L. casei DG® treatment induced a statistically significant decrease in both (p < 0.001) symptomatic recur-rence [1.9/3 months vs 0.5/3 months] and antibiotic use [− 7938 UDD]. No clinically relevant adverse effects were reported.

CONCLUSIONS:
L. casei DG® prevents symptomatic recurrences and improves the quality of life in patients with CBP, reduc-ing the antibiotic use.

Authors
Tommaso Cai · Luca Gallelli · Erika Cione · Gianpaolo Perletti · Francesco Ciarleglio · Gianni Malossini · Giovanni De Pretis · Alessandro Palmieri · Vincenzo Mirone · Riccardo Bartoletti · Truls E. Bjerklund Johansen

Cookie Policy

This website uses technical and profiling cookies collecting data in aggregate form. By closing this banner, scrolling this page or clicking any of its elements you consent to the use of cookies.

Healthcare professionals

Part of the information contained in this website is exclusively addressed to healthcare professionals. Please confirm that you are a healthcare professional. Are you a healthcare professional?

Yes, I am
No, I am not
Content to third part

This website contains links/references to third-party websites. By such links, SOFAR does not provide any guarantee nor gives its approval to their contents and quality. SOFAR does not have and does not accept any responsibility for the contents or the availability of such websites; SOFAR does not accept any liability for damage or injury resulting from the use of such contents, of whatever form. Users access such websites at their own risk. The information contained in this website is for information purposes only and not for diagnostic or therapeutic purposes. Thus, it does not substitute in any way medical and /or expert or other healthcare professionals or specialists ‘advice.

Duly noted